Fluoropyrimidines in the Treatment of Advanced Neoplastic Diseases: Role and Advantages of UFT

Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Emilio Bajetta(Fondazione Lanza), Giuseppina Busto(Fondazione IRCCS Istituto Nazionale dei Tumori), Giuseppe Procopio(Fondazione IRCCS Istituto Nazionale dei Tumori), Antonino Cassata(Fondazione IRCCS Istituto Nazionale dei Tumori), Luigi Celio, Paola Pozzi(Fondazione IRCCS Istituto Nazionale dei Tumori)
Tumori Journal
January 1, 1999
10.1177/030089169908500102
Cited by 8

Related Papers

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780